Drug Profile
Preladenant
Alternative Names: MK-3814; Privadenant; SCH 420814Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co; Schering-Plough
- Class Antiparkinsonians; Bridged-ring heterocyclic compounds; Piperazines; Small molecules
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Parkinson's disease
Most Recent Events
- 17 Feb 2021 No development reported - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel, Canada, USA (PO)
- 17 Feb 2021 No development reported - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Israel, Canada, USA (PO)
- 24 Nov 2017 Merck terminates phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Canada, Israel, because the data did not support study endpoints (PO) (NCT03099161)